Zoominfo, which is readying to IPO, launched a Health Scan Analysis to help firms identify “key segments for opportunities” within their Total Addressable Market (TAM).  The service identifies targetable market segments that are less impacted by COVID along with which segments to avoid.  Firms can then “quickly pivot their go-to-market strategy and focus their efforts on worthwhile prospects ready to buy.”

The Health Scan begins with a consultation where customers share details about their pipeline and business challenges.  Zoominfo’s data solutions team then analyzes the company’s pipeline and win-rate trends before and during the downturn.  The analysis includes “benchmarks to pinpoint where any pipeline degradation may have occurred.”

The Data Solutions team conducts a market assessment that identifies opportunities and sizes their TAM.  The report also includes a market segmentation analysis and a “hand-selected list” of targets from Zoominfo’s database of companies and contacts.

“Recognizing that current market conditions are extraordinarily challenging, it’s more important than ever to ensure that our customers are generating high-quality contacts for their pipeline.  We discovered valuable takeaways when examining our own position in this same manner.  As a result, we’re offering our clients these data-driven insights on how to optimize their go-to-market strategies so they can continue to hit their numbers and thrive in a changing market.”

ZoomInfo CEO Henry Schuck

From the initial interview through report delivery [Sample PDF], Zoominfo promises a five business-day turnaround.

Zoominfo is not the only firm that provides pipeline analyses. Dun & Bradstreet offers a similar analytics service which combines firmographics with industry risk data and InsideView offers Apex.